Table 1.
Basic characteristics of subjects with Parkinson's disease.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | |
|---|---|---|---|---|---|---|---|---|
| Age/gender | 67/M | 57/M | 66/F | 70/F | 61/M | 50/M | 78/M | 76/F |
| Disease duration (years) | 5 | 11 | 11 | 12 | 11 | 10 | 10 | 17 |
| Hypertension | − | − | − | + | − | − | − | − |
| Body mass index | 20.5 | 19.4 | 20.2 | 22.6 | 27.2 | 19.4 | 21.7 | 16.1 |
| Hoehn–Yahr stage | 2 | 2 | 2 | 4 | 4 | 4 | 4 | 5 |
| MDS-UPDRS part 3 | 32 | 10 | 7 | 38 | 22 | 25 | 28 | 57 |
| MDS-UPDRS part 4 | 5 | 11 | 4 | 7 | 7 | 7 | 4 | 7 |
| MoCA-J | 25 | 23 | 26 | 22 | 25 | 29 | 26 | 23 |
| Psychosis∗ | 0 | 2 | 2 | 11 | 4 | 0 | 3 | 0 |
| Anxiety∗ | 2 | 12 | 0 | 3 | 17 | 6 | 6 | 2 |
| Levodopa (mg/day) | 50 | 700 | 600 | 400 | 550 | LCIG | 1100 | 400 |
| Dopamine agonists (DA) | + | + | + | + | + | − | + | + |
| Long-acting DA | + | + | + | + | + | − | + | + |
| Sleeping drug | − | + | − | + | + | − | − | + |
| PDSS-2 total score | 17 | 32 | 21 | 21 | 20 | 27 | 43 | 36 |
| Disturbed sleep on PDSS-2 | 10 | 15 | 14 | 13 | 9 | 14 | 15 | 10 |
| Motor symptoms at night on PDSS-2 | 4 | 9 | 4 | 2 | 5 | 8 | 15 | 11 |
| PD symptoms at night on PDSS-2 | 3 | 7 | 3 | 6 | 6 | 5 | 13 | 14 |
| PSQI total score | 6 | 14 | 13 | 15 | 14 | 10 | 15 | 10 |
| Beck depression score | 14 | 28 | 16 | 21 | 23 | 20 | 27 | 20 |
| RBD score | 9 | 7 | 2 | 9 | 2 | 4 | 12 | 6 |
MDS-UPDRS: Movement Disorder Society Revision of the Unified PD Rating Scale; LCIG: continuous intrajejunal infusion of levodopa-carbidopa intestinal; MoCA-J: Japanese version of the Montreal Cognitive Assessment; PDSS: PD Sleep Scale; PSQI: Pittsburgh Sleep Questionnaire Index; RBD: REM sleep behavior disorder. ∗MDS-Non-Motor Rating Scale.